Skip to main content
Fig. 7 | BMC Cancer

Fig. 7

From: Acteoside as a potential therapeutic option for primary hepatocellular carcinoma: a preclinical study

Fig. 7

Changes of kallikrein-related peptidase (KLK) mRNA levels and tumor suppressor protein p53 levels following treatment of JHH-7 cells with acteoside. a-e, The down-regulation of KLK1, 2, 4, 9 and 10 mRNA levels was observed by acteoside (A01) at 350 or 700 μM (A01–350 or A01–700). f, Changes of p53 by western blot analyses. Treatment with acteoside (A01) increased p53 levels. Data are expressed as mean ± SEM (n = 4/group). *,p < 0.05 vs the control group; **,p < 0.01 vs the control group

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us